Clinical characteristics and prognosis of therapy-related acute myeloid leukemia patients with RUNX1::RUNX1T1

Résumé fourni par la source

BACKGROUND: This study aimed to analyze the clinical characteristics and prognostic factors in therapy-related acute myeloid leukemia (t-AML) patients with RUNX1::RUNX1T1 fusion. METHODS: A retrospective analysis was performed. Twenty-three t-AML patients with RUNX1::RUNX1T1 were included as the case group. Ninety-two de novo AML patients with RUNX1::RUNX1T1 were randomly selected using the case-pair method in a 1:4 ratio who matched for (1) sex, (2) age (± 5 years), (3) time of diagnosis (± 3 years). A total of 115 AML patients with RUNX1::RUNX1T1 were enrolled. RESULTS: The CR rate after two cycles in t-AML patients with RUNX1::RUNX1T1 was same to that in de novo AML patients with RUNX1::RUNX1T1(95.6% vs. 95.6%, p = 0.48). Survival analysis indicated the 3-year overall survival (OS) of t-AML and de novo AML patients with RUNX1::RUNX1T1 were 68.2% vs. 83.1% (P = 0.23), and 3-year disease-free survival (DFS) were 60.9% vs. 65.3% (P = 0.84). Multivariate analysis demonstrated that age ≥ 60 years, CCND3, DNMT3A and FLT3 mutation were independent adverse factors, but achieving MMR after three cycles were independent favorable factors for survival of AML patients with RUNX1::RUNX1T1. CONCLUSIONS: This study showed no significant differences in remission rates and survival between the two groups. Multivariate analysis demonstrated that age ≥ 60 years, CCND3, DNMT3A and FLT3 mutation were independent adverse factors, but achieving MMR after three cycles were independent favorable factors for survival.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.